clomipramine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
substances of the imipramine group 701 303-49-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clomipramine
  • chlorimipramine
  • clomipramine hydrochloride
  • clomipramine HCl
A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.
  • Molecular weight: 314.86
  • Formula: C19H23ClN2
  • CLOGP: 5.92
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.34
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O
0.10 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.24 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 51 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 13 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.03 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 26 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1989 FDA MALLINCKRODT LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 214.31 16.20 137 10745 59518 56221667
Intentional overdose 190.73 16.20 134 10748 67983 56213202
Serotonin syndrome 173.44 16.20 90 10792 26400 56254785
Drug interaction 149.74 16.20 193 10689 209562 56071623
Suicide attempt 130.65 16.20 100 10782 57736 56223449
Overdose 129.55 16.20 129 10753 105701 56175484
Bezoar 116.99 16.20 31 10851 1337 56279848
Poisoning deliberate 111.66 16.20 49 10833 9904 56271281
Toxicity to various agents 102.11 16.20 167 10715 224397 56056788
Intentional self-injury 98.66 16.20 61 10821 24931 56256254
Depressed level of consciousness 86.55 16.20 78 10804 56355 56224830
Antipsychotic drug level increased 82.87 16.20 29 10853 3213 56277972
Neuroleptic malignant syndrome 77.96 16.20 40 10842 11438 56269747
Sopor 74.88 16.20 48 10834 20874 56260311
Electrocardiogram QT prolonged 67.54 16.20 67 10815 54521 56226664
Tachycardia 65.47 16.20 91 10791 105785 56175400
Antidepressant drug level increased 58.65 16.20 13 10869 260 56280925
Altered state of consciousness 56.79 16.20 42 10840 22979 56258206
Hypertonia 55.32 16.20 23 10859 4069 56277116
International normalised ratio abnormal 55.06 16.20 21 10861 2967 56278218
Hyperthermia 50.90 16.20 27 10855 8258 56272927
Suicidal ideation 50.50 16.20 59 10823 57683 56223502
Pain 49.49 16.20 34 10848 663150 55618035
Drug abuse 49.27 16.20 63 10819 67547 56213638
Cerebellar syndrome 48.61 16.20 20 10862 3447 56277738
Agitation 48.58 16.20 57 10825 55979 56225206
Somnolence 48.20 16.20 101 10781 163312 56117873
Myoclonus 47.38 16.20 32 10850 15171 56266014
Tremor 46.91 16.20 84 10798 121005 56160180
Rheumatoid arthritis 46.20 16.20 9 10873 382595 55898590
Sinus tachycardia 44.56 16.20 36 10846 22408 56258777
Akathisia 44.31 16.20 25 10857 8627 56272558
Livedo reticularis 42.23 16.20 16 10866 2219 56278966
Confusional state 42.10 16.20 111 10771 208044 56073141
Hypotension 39.40 16.20 122 10760 250386 56030799
Polyuria 39.16 16.20 22 10860 7529 56273656
Joint swelling 39.06 16.20 5 10877 289795 55991390
Hyposmia 38.82 16.20 11 10871 610 56280575
Psychomotor hyperactivity 38.81 16.20 24 10858 9796 56271389
Ventricular dyskinesia 38.01 16.20 8 10874 124 56281061
Obsessive-compulsive disorder 37.56 16.20 17 10865 3689 56277496
Hyperchloraemia 36.96 16.20 11 10871 726 56280459
Mental disorder 36.89 16.20 33 10849 23571 56257614
Arthralgia 35.68 16.20 27 10855 501642 55779543
Alopecia 35.20 16.20 7 10875 293451 55987734
Pneumonia aspiration 33.25 16.20 36 10846 32375 56248810
Poisoning 33.00 16.20 24 10858 12789 56268396
Urinary retention 32.03 16.20 33 10849 28041 56253144
Parkinsonism 31.93 16.20 21 10861 9525 56271660
Hypotonia 31.26 16.20 20 10862 8657 56272528
Fatigue 30.70 16.20 67 10815 788485 55492700
Diarrhoea 30.36 16.20 48 10834 638459 55642726
Restlessness 29.88 16.20 31 10851 26555 56254630
Muscle rigidity 29.81 16.20 21 10861 10650 56270535
Disturbance in attention 29.70 16.20 34 10848 32506 56248679
Cor pulmonale acute 29.60 16.20 8 10874 372 56280813
Drug withdrawal syndrome neonatal 29.52 16.20 12 10870 2004 56279181
Mydriasis 29.11 16.20 21 10861 11050 56270135
Psychomotor skills impaired 28.83 16.20 12 10870 2128 56279057
Newborn persistent pulmonary hypertension 28.43 16.20 7 10875 224 56280961
Miosis 28.33 16.20 17 10865 6575 56274610
Post-anoxic myoclonus 27.49 16.20 5 10877 34 56281151
Inappropriate antidiuretic hormone secretion 27.16 16.20 22 10860 13734 56267451
Urine osmolarity increased 27.07 16.20 6 10876 120 56281065
Blood prolactin increased 26.80 16.20 13 10869 3296 56277889
Drug level increased 26.65 16.20 26 10856 20699 56260486
Otorrhoea 26.46 16.20 10 10872 1377 56279808
Hallucination, auditory 26.14 16.20 20 10862 11504 56269681
Retroplacental haematoma 25.83 16.20 6 10876 149 56281036
Shock 25.62 16.20 26 10856 21702 56259483
Psychomotor retardation 25.53 16.20 13 10869 3656 56277529
Onychophagia 25.02 16.20 5 10877 59 56281126
Circulatory collapse 24.72 16.20 25 10857 20778 56260407
Hepatocellular injury 24.69 16.20 28 10854 26486 56254699
Cyanosis 24.50 16.20 22 10860 15788 56265397
Product dose omission issue 24.29 16.20 5 10877 204748 56076437
Depression 24.03 16.20 83 10799 180034 56101151
Mania 23.97 16.20 19 10863 11501 56269684
Spasmodic dysphonia 23.67 16.20 5 10877 79 56281106
Rash 23.46 16.20 37 10845 493010 55788175
Contraindicated product administered 23.27 16.20 4 10878 186282 56094903
Electrocardiogram QRS complex prolonged 23.24 16.20 14 10868 5453 56275732
Nasopharyngitis 23.11 16.20 7 10875 220952 56060233
Apathy 23.03 16.20 16 10866 7938 56273247
Hypokalaemia 22.88 16.20 54 10828 94383 56186802
Nephrogenic diabetes insipidus 22.80 16.20 8 10874 892 56280293
Treatment failure 22.79 16.20 3 10879 170389 56110796
Lactic acidosis 22.74 16.20 31 10851 35315 56245870
Therapeutic product effect decreased 22.63 16.20 3 10879 169449 56111736
Asphyxia 22.50 16.20 14 10868 5775 56275410
Hyponatraemia 22.18 16.20 56 10826 102083 56179102
Peripheral swelling 21.88 16.20 9 10873 234717 56046468
Arthropathy 21.58 16.20 6 10876 200269 56080916
Anxiety 21.54 16.20 84 10798 193088 56088097
Paralogism 21.42 16.20 4 10878 32 56281153
Swelling 21.08 16.20 10 10872 239761 56041424
Cholestasis 21.06 16.20 26 10856 26887 56254298
Right ventricular dilatation 20.99 16.20 8 10874 1128 56280057
Hyperhidrosis 20.87 16.20 52 10830 94036 56187149
Tardive dyskinesia 20.58 16.20 15 10867 8016 56273169
Drug hypersensitivity 20.58 16.20 14 10868 275191 56005994
Foetal arrhythmia 20.37 16.20 5 10877 158 56281027
Heat stroke 20.25 16.20 7 10875 747 56280438
Dialysis 20.18 16.20 16 10866 9686 56271499
Stereotypy 19.87 16.20 6 10876 416 56280769
Infection 19.78 16.20 7 10875 200199 56080986
Drug screen false positive 19.68 16.20 7 10875 813 56280372
Respiratory depression 18.67 16.20 17 10865 12418 56268767
Hypernatraemia 18.42 16.20 13 10869 6607 56274578
Hyporesponsive to stimuli 18.34 16.20 7 10875 991 56280194
Acquired haemophilia 18.16 16.20 7 10875 1017 56280168
Rhabdomyolysis 18.07 16.20 30 10852 40628 56240557
Morbid thoughts 18.03 16.20 6 10876 570 56280615
Loss of consciousness 17.83 16.20 54 10828 109295 56171890
Toxic skin eruption 17.53 16.20 16 10866 11723 56269462
Headache 17.45 16.20 53 10829 558991 55722194
Otitis media 17.31 16.20 11 10871 4705 56276480
Hyperprolactinaemia 17.20 16.20 10 10872 3651 56277534
Abdominal discomfort 17.14 16.20 17 10865 277257 56003928
Intestinal gangrene 17.12 16.20 3 10879 16 56281169
Psychiatric symptom 17.04 16.20 11 10871 4833 56276352
Anticholinergic syndrome 16.88 16.20 8 10874 1926 56279259
Junctional ectopic tachycardia 16.73 16.20 4 10878 113 56281072

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Obsessive-compulsive disorder 299.12 20.90 90 7716 4847 31684691
Suicide attempt 271.20 20.90 147 7659 37101 31652437
Therapeutic product effect variable 260.09 20.90 66 7740 1872 31687666
Antipsychotic drug level below therapeutic 252.65 20.90 65 7741 1950 31687588
Disinhibition 238.56 20.90 66 7740 2627 31686911
Euphoric mood 219.55 20.90 71 7735 4849 31684689
Akathisia 203.70 20.90 74 7732 7179 31682359
Increased appetite 186.66 20.90 67 7739 6277 31683261
Toxicity to various agents 132.50 20.90 191 7615 181296 31508242
Intentional overdose 132.22 20.90 97 7709 41292 31648246
Serotonin syndrome 103.79 20.90 62 7744 18711 31670827
Coma 99.92 20.90 82 7724 41068 31648470
Poisoning deliberate 95.17 20.90 43 7763 7301 31682237
Neuroleptic malignant syndrome 91.40 20.90 55 7751 16814 31672724
Dyslipidaemia 81.39 20.90 37 7769 6369 31683169
Electrocardiogram QT prolonged 80.47 20.90 70 7736 37917 31651621
Therapeutic product effect incomplete 79.70 20.90 74 7732 43622 31645916
Leukaemia 76.78 20.90 31 7775 3994 31685544
Obesity 72.85 20.90 41 7765 11059 31678479
Leukopenia 69.15 20.90 78 7728 57750 31631788
Prescribed overdose 68.72 20.90 37 7769 9155 31680383
Weight increased 67.21 20.90 92 7714 82855 31606683
Sopor 63.42 20.90 38 7768 11514 31678024
Intentional self-injury 60.93 20.90 39 7767 13276 31676262
Extrapyramidal disorder 52.65 20.90 34 7772 11744 31677794
Somnolence 50.60 20.90 89 7717 99356 31590182
Agitation 46.75 20.90 62 7744 54107 31635431
Overdose 45.97 20.90 78 7728 84586 31604952
Compartment syndrome 42.24 20.90 18 7788 2653 31686885
Drug interaction 40.63 20.90 128 7678 208415 31481123
Schizoaffective disorder 39.49 20.90 14 7792 1261 31688277
Renal hypertension 38.77 20.90 9 7797 173 31689365
Loose associations 35.91 20.90 7 7799 55 31689483
Mania 35.00 20.90 24 7782 9153 31680385
Brachial plexus injury 34.05 20.90 7 7799 74 31689464
Tremor 30.86 20.90 62 7744 76358 31613180
Fatigue 30.39 20.90 23 7783 335183 31354355
Rhabdomyolysis 29.86 20.90 55 7751 63526 31626012
Hypothermia 29.58 20.90 22 7784 9522 31680016
Aggression 28.10 20.90 40 7766 37251 31652287
Hypertonia neonatal 26.54 20.90 8 7798 431 31689107
Inappropriate antidiuretic hormone secretion 26.15 20.90 22 7784 11365 31678173
Coma scale abnormal 25.09 20.90 14 7792 3709 31685829
Pneumonia 24.49 20.90 28 7778 335284 31354254
Diarrhoea 24.07 20.90 31 7775 352378 31337160
Cataplexy 23.69 20.90 7 7799 352 31689186
Cough 23.05 20.90 3 7803 134811 31554727
Drug ineffective 22.99 20.90 171 7635 395402 31294136
Depressed level of consciousness 22.84 20.90 37 7769 38564 31650974
Bradykinesia 22.83 20.90 13 7793 3579 31685959
Dyspraxia 22.63 20.90 7 7799 412 31689126
Pain 22.40 20.90 9 7797 186750 31502788
Hyperthermia 22.29 20.90 19 7787 9985 31679553
Drug withdrawal syndrome 21.87 20.90 25 7781 18725 31670813
Hallucination, auditory 21.72 20.90 19 7787 10341 31679197
Feelings of worthlessness 20.91 20.90 6 7800 272 31689266

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 309.24 16.87 211 15082 91633 70821518
Intentional overdose 270.91 16.87 200 15093 98235 70814916
Suicide attempt 263.62 16.87 181 15112 79329 70833822
Serotonin syndrome 258.12 16.87 142 15151 41972 70871179
Poisoning deliberate 192.13 16.87 87 15206 16973 70896178
Neuroleptic malignant syndrome 174.05 16.87 93 15200 25914 70887237
Drug interaction 159.13 16.87 290 15003 381151 70532000
Overdose 150.46 16.87 184 15109 169561 70743590
Toxicity to various agents 149.91 16.87 283 15010 381889 70531262
Sopor 134.83 16.87 84 15209 31183 70881968
Bezoar 127.32 16.87 38 15255 2268 70910883
Electrocardiogram QT prolonged 124.06 16.87 119 15174 83398 70829753
Intentional self-injury 104.61 16.87 72 15221 31578 70881573
Obsessive-compulsive disorder 102.90 16.87 40 15253 5330 70907821
Somnolence 90.97 16.87 165 15128 215441 70697710
Akathisia 85.15 16.87 45 15248 12248 70900903
Hyperthermia 74.92 16.87 46 15247 16625 70896526
Depressed level of consciousness 74.46 16.87 93 15200 87338 70825813
Agitation 72.71 16.87 95 15198 93280 70819871
Altered state of consciousness 65.07 16.87 60 15233 39962 70873189
Suicidal ideation 62.42 16.87 76 15217 69520 70843631
Tremor 61.67 16.87 116 15177 155508 70757643
Tachycardia 60.14 16.87 116 15177 158430 70754721
Pain 59.20 16.87 31 15262 628785 70284366
Mania 58.94 16.87 40 15253 17134 70896017
Antidepressant drug level increased 57.24 16.87 14 15279 389 70912762
Antipsychotic drug level increased 55.76 16.87 26 15267 5414 70907737
Psychomotor hyperactivity 53.09 16.87 36 15257 15397 70897754
Confusional state 52.22 16.87 157 15136 284241 70628910
Rhabdomyolysis 51.86 16.87 82 15211 95678 70817473
Parkinsonism 48.59 16.87 34 15259 15291 70897860
Diarrhoea 45.14 16.87 62 15231 783279 70129872
Antipsychotic drug level below therapeutic 44.86 16.87 14 15279 971 70912180
Fatigue 44.80 16.87 68 15225 824251 70088900
Shock 44.38 16.87 49 15244 40376 70872775
Arthralgia 44.19 16.87 27 15266 503363 70409788
Extrapyramidal disorder 43.58 16.87 36 15257 20714 70892437
Inappropriate antidiuretic hormone secretion 41.97 16.87 37 15256 23239 70889912
Myoclonus 41.84 16.87 39 15254 26316 70886835
Cerebellar syndrome 41.55 16.87 21 15272 5210 70907941
International normalised ratio abnormal 41.49 16.87 21 15272 5226 70907925
Hallucination, auditory 41.02 16.87 33 15260 18295 70894856
Pneumonia aspiration 40.35 16.87 58 15235 62231 70850920
Drug abuse 38.82 16.87 93 15200 147163 70765988
Renal hypertension 38.68 16.87 9 15284 201 70912950
Joint swelling 37.72 16.87 5 15288 253206 70659945
Psychomotor retardation 37.37 16.87 20 15273 5578 70907573
Therapeutic product effect variable 37.29 16.87 14 15279 1696 70911455
Sinus tachycardia 37.04 16.87 41 15252 33872 70879279
Peripheral swelling 36.90 16.87 4 15289 236559 70676592
Nasopharyngitis 36.66 16.87 3 15290 222203 70690948
Disinhibition 36.64 16.87 15 15278 2286 70910865
Loose associations 36.51 16.87 7 15286 58 70913093
Muscle rigidity 36.36 16.87 31 15262 18619 70894532
Polyuria 36.24 16.87 27 15266 13379 70899772
Euphoric mood 36.12 16.87 21 15272 6868 70906283
Compartment syndrome 35.60 16.87 18 15275 4468 70908683
Rheumatoid arthritis 34.62 16.87 10 15283 291795 70621356
Hypertonia 34.58 16.87 20 15273 6478 70906673
Apathy 34.48 16.87 25 15268 11883 70901268
Hepatocellular injury 34.47 16.87 46 15247 46045 70867106
Hyposmia 33.11 16.87 10 15283 621 70912530
Livedo reticularis 32.39 16.87 16 15277 3782 70909369
Hyperchloraemia 32.35 16.87 11 15282 1001 70912150
Mental disorder 32.33 16.87 35 15258 28205 70884946
Brachial plexus injury 32.17 16.87 7 15286 114 70913037
Mydriasis 31.80 16.87 27 15266 16126 70897025
Bronchial hyperreactivity 31.48 16.87 14 15279 2612 70910539
Hyperhidrosis 31.39 16.87 80 15213 131506 70781645
Urinary retention 31.26 16.87 47 15246 52473 70860678
Bradykinesia 29.44 16.87 19 15274 7483 70905668
Electrocardiogram QRS complex prolonged 29.34 16.87 21 15272 9785 70903366
Infusion related reaction 29.18 16.87 4 15289 197530 70715621
Circulatory collapse 29.00 16.87 37 15256 35437 70877714
Rash 28.75 16.87 41 15252 510521 70402630
Miosis 28.64 16.87 24 15269 14077 70899074
Pressure of speech 28.25 16.87 10 15283 1025 70912126
Schizoaffective disorder 28.22 16.87 12 15281 2011 70911140
Ventricular dyskinesia 28.17 16.87 8 15285 400 70912751
Coma scale abnormal 28.07 16.87 19 15274 8097 70905054
Restlessness 26.94 16.87 39 15254 42089 70871062
Seizure 26.92 16.87 92 15201 177870 70735281
Depression 26.79 16.87 99 15194 198875 70714276
Loss of consciousness 26.69 16.87 84 15209 155632 70757519
Retroplacental haematoma 26.61 16.87 6 15287 116 70913035
Prescribed overdose 26.52 16.87 31 15262 27150 70886001
Abdominal pain 26.47 16.87 21 15272 342106 70571045
Disturbance in attention 26.40 16.87 39 15254 42855 70870296
Intentional product misuse 26.27 16.87 55 15238 79540 70833611
Febrile neutropenia 26.14 16.87 6 15287 204312 70708839
Asphyxia 26.12 16.87 20 15273 10322 70902829
Anxiety 25.89 16.87 105 15188 220225 70692926
Poisoning 25.83 16.87 28 15265 22594 70890557
Nausea 25.66 16.87 96 15197 851992 70061159
Speech disorder 25.57 16.87 42 15251 50538 70862613
Breast disorder 25.34 16.87 11 15282 1938 70911213
Drug level increased 25.15 16.87 35 15258 36434 70876717
Hypotension 25.11 16.87 161 15132 404220 70508931
Post-anoxic myoclonus 24.80 16.87 5 15288 55 70913096
Product dose omission issue 24.79 16.87 8 15285 217460 70695691
Hypothermia 24.41 16.87 26 15267 20568 70892583
Generalised tonic-clonic seizure 24.39 16.87 37 15256 41624 70871527
Cor pulmonale acute 24.37 16.87 8 15285 653 70912498
Otorrhoea 23.91 16.87 10 15283 1608 70911543
Blood prolactin increased 23.91 16.87 13 15280 3741 70909410
Withdrawal syndrome 23.63 16.87 28 15265 24876 70888275
Pain in extremity 23.12 16.87 22 15271 328060 70585091
Cough 22.72 16.87 22 15271 325355 70587796
Psychomotor skills impaired 22.31 16.87 13 15280 4271 70908880
Pneumonia 22.23 16.87 61 15232 596171 70316980
Onychophagia 22.06 16.87 5 15288 99 70913052
Obesity 22.01 16.87 28 15265 26743 70886408
Psychiatric symptom 21.67 16.87 15 15278 6629 70906522
Abulia 21.65 16.87 8 15285 927 70912224
Urine osmolarity increased 21.61 16.87 6 15287 276 70912875
Aggression 21.54 16.87 38 15255 48408 70864743
Dyspraxia 21.53 16.87 6 15287 280 70912871
Alopecia 21.42 16.87 8 15285 198482 70714669
Paralogism 20.99 16.87 4 15289 32 70913119
Cataplexy 20.98 16.87 8 15285 1011 70912140
Heat stroke 20.90 16.87 9 15284 1554 70911597
Therapeutic product effect decreased 20.87 16.87 3 15290 143015 70770136
Pleurothotonus 20.27 16.87 10 15283 2356 70910795
Clonus 20.09 16.87 14 15279 6254 70906897
Arthropathy 20.02 16.87 4 15289 150053 70763098
Hypokalaemia 19.98 16.87 68 15225 131120 70782031
Morbid thoughts 19.48 16.87 7 15286 749 70912402
Nephrogenic diabetes insipidus 18.94 16.87 9 15284 1954 70911197
Hypernatraemia 18.57 16.87 18 15275 12743 70900408
Obsessive-compulsive symptom 18.57 16.87 5 15288 205 70912946
Dyslipidaemia 18.43 16.87 16 15277 9844 70903307
Product use in unapproved indication 18.43 16.87 91 15202 207387 70705764
Headache 18.35 16.87 64 15229 580341 70332810
Social anxiety disorder 18.28 16.87 6 15287 489 70912662
Major depression 18.26 16.87 15 15278 8559 70904592
Spasmodic dysphonia 18.25 16.87 5 15288 219 70912932
Feelings of worthlessness 18.21 16.87 6 15287 495 70912656
Anticholinergic syndrome 18.10 16.87 10 15283 2970 70910181
Stomatitis 18.06 16.87 3 15290 128508 70784643
Hyperreflexia 17.94 16.87 14 15279 7428 70905723
Disorientation 17.92 16.87 39 15254 57884 70855267
Hypersensitivity 17.90 16.87 14 15279 229798 70683353
Sepsis 17.69 16.87 16 15277 244529 70668622
Completed suicide 17.66 16.87 96 15197 227039 70686112
Blood creatine phosphokinase increased 17.55 16.87 40 15253 61223 70851928
Increased appetite 17.41 16.87 16 15277 10597 70902554
Drug screen false positive 17.36 16.87 7 15286 1026 70912125
Stupor 17.35 16.87 13 15280 6496 70906655
Hepatic cytolysis 17.26 16.87 21 15272 19171 70893980
Right ventricular dilatation 17.19 16.87 8 15285 1657 70911494
Hypovolaemic shock 17.13 16.87 16 15277 10821 70902330
Contraindicated product administered 17.12 16.87 4 15289 134608 70778543
Irritability 17.02 16.87 30 15263 38195 70874956
Hyponatraemia 17.00 16.87 74 15219 160013 70753138
Death 16.96 16.87 55 15238 510006 70403145

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AA04 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Non-selective monoamine reuptake inhibitors
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:48278 serotonergic drugs
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:149553 anticoronaviral drug
MeSH PA D000928 Antidepressive Agents
MeSH PA D000929 Antidepressive Agents, Tricyclic
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018490 Serotonin Agents
MeSH PA D017367 Serotonin Uptake Inhibitors
FDA EPC N0000175752 Tricyclic Antidepressant
CHEBI has role CHEBI:50949 SSRI
CHEBI has role CHEBI:77402 EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Obsessive-compulsive disorder indication 191736004 DOID:10933
Depressive disorder off-label use 35489007
Cataplexy off-label use 46263000
Anxiety off-label use 48694002
Panic disorder off-label use 371631005 DOID:594
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Glaucoma contraindication 23986001 DOID:1686
Hyperthyroidism contraindication 34486009 DOID:7998
Acute nephropathy contraindication 58574008
Epilepsy contraindication 84757009 DOID:1826
Bipolar affective disorder, current episode manic contraindication 191618007
Disease of liver contraindication 235856003 DOID:409
Retention of urine contraindication 267064002
Pheochromocytoma contraindication 302835009
Malignant hyperthermia contraindication 405501007
Myocardial infarction in recovery phase contraindication 418044006
Neuroblastoma contraindication 432328008 DOID:769
Atrioventricular Conduction Defect contraindication




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Separation anxiety Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Clomicalm Tablets Virbac AH Inc. 1
Clomipramine Hydrochloride Tablets Mizner Bioscience LLC 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.04 Basic
pKa2 6.19 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Kd 7.42 WOMBAT-PK IUPHAR
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 9.70 PDSP CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.28 PDSP
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.24 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 7.45 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 6.82 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.19 PDSP
5-hydroxytryptamine receptor 6 GPCR Ki 6.95 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 8.50 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 7.34 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 7.41 PDSP
Histamine H1 receptor GPCR Ki 8.01 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.70 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 7.66 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 7.07 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 7.44 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 7.89 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 7.42 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 6.32 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 6.69 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter IC50 5.56 CHEMBL
Cytochrome P450 2D6 Enzyme Ki 5.66 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 7.40 DRUG MATRIX
Glutathione S-transferase P Enzyme WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 4.71 CHEMBL
D(1A) dopamine receptor GPCR Ki 6.66 PDSP
D(2) dopamine receptor GPCR Ki 6.95 PDSP
Trypanothione reductase Enzyme Ki 5.19 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 7.14 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.94 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 10.40 CHEMBL
D(2) dopamine receptor GPCR Ki 7.25 CHEMBL
Sodium-dependent noradrenaline transporter Transporter IC50 6.05 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 7.15 CHEMBL
Histamine H1 receptor GPCR IC50 9.70 CHEMBL
Serotonin (5-HT) receptor GPCR IC50 8.30 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR Ki 5.30 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 7.29 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 8.08 CHEMBL
Trypanothione reductase Enzyme IC50 5.47 CHEMBL
G protein-activated inward rectifier potassium channel 2 Ion channel BLOCKER IC50 4.40 IUPHAR

External reference:

IDSource
4019687 VUID
N0000147779 NUI
D00811 KEGG_DRUG
17321-77-6 SECONDARY_CAS_RN
2597 RXNORM
4019492 VANDF
4019687 VANDF
C0009010 UMLSCUI
CHEBI:47780 CHEBI
CXX PDB_CHEM_ID
CHEMBL415 ChEMBL_ID
CHEMBL1200710 ChEMBL_ID
DB01242 DRUGBANK_ID
D002997 MESH_DESCRIPTOR_UI
2801 PUBCHEM_CID
2398 IUPHAR_LIGAND_ID
2238 INN_ID
NUV44L116D UNII
373 MMSL
4476 MMSL
d00876 MMSL
003456 NDDF
004614 NDDF
372903001 SNOMEDCT_US
387027004 SNOMEDCT_US
96209002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-3025 CAPSULE 25 mg ORAL ANDA 25 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-3050 CAPSULE 50 mg ORAL ANDA 25 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-3075 CAPSULE 75 mg ORAL ANDA 25 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0406-8806 CAPSULE 25 mg ORAL NDA 24 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0406-8807 CAPSULE 50 mg ORAL NDA 24 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0406-8808 CAPSULE 75 mg ORAL NDA 24 sections
ANAFRANIL HUMAN PRESCRIPTION DRUG LABEL 1 0406-9906 CAPSULE 25 mg ORAL NDA 24 sections
ANAFRANIL HUMAN PRESCRIPTION DRUG LABEL 1 0406-9907 CAPSULE 50 mg ORAL NDA 24 sections
ANAFRANIL HUMAN PRESCRIPTION DRUG LABEL 1 0406-9908 CAPSULE 75 mg ORAL NDA 24 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2027 CAPSULE 25 mg ORAL ANDA 25 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2037 CAPSULE 50 mg ORAL ANDA 25 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0630 CAPSULE 25 mg ORAL ANDA 24 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0631 CAPSULE 50 mg ORAL ANDA 24 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0632 CAPSULE 75 mg ORAL ANDA 24 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7038 CAPSULE 25 mg ORAL ANDA 26 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7039 CAPSULE 50 mg ORAL ANDA 26 sections
clomiPRAMINE Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-698 CAPSULE 25 mg ORAL ANDA 27 sections
clomiPRAMINE Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-699 CAPSULE 50 mg ORAL ANDA 27 sections
clomiPRAMINE Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-700 CAPSULE 75 mg ORAL ANDA 27 sections
Clomipramine Hydrochloride Human Prescription Drug Label 1 16571-683 CAPSULE 25 mg ORAL ANDA 23 sections
Clomipramine Hydrochloride Human Prescription Drug Label 1 16571-684 CAPSULE 50 mg ORAL ANDA 23 sections
Clomipramine Hydrochloride Human Prescription Drug Label 1 16571-685 CAPSULE 75 mg ORAL ANDA 23 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-849 CAPSULE 25 mg ORAL ANDA 21 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-850 CAPSULE 50 mg ORAL ANDA 21 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-851 CAPSULE 75 mg ORAL ANDA 21 sections
Clomipramine hydrochloride Human Prescription Drug Label 1 27241-210 CAPSULE 25 mg ORAL ANDA 23 sections
Clomipramine hydrochloride Human Prescription Drug Label 1 27241-211 CAPSULE 50 mg ORAL ANDA 23 sections
Clomipramine hydrochloride Human Prescription Drug Label 1 27241-212 CAPSULE 75 mg ORAL ANDA 23 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42571-342 CAPSULE 25 mg ORAL ANDA 23 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42571-343 CAPSULE 50 mg ORAL ANDA 23 sections